FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1846747462> ?p ?o ?g. }

• W1846747462 endingPage "2885" @default.
• W1846747462 startingPage "2879" @default.
• W1846747462 abstract "PURPOSE The purpose of this study was to evaluate the clinical efficacy and safety of docetaxel in patients with metastatic breast cancer (MBC) resistant to doxorubicin or mitoxantrone. PATIENTS AND METHODS Docetaxel 100 mg/m2 was administered as a 1-hour intravenous (IV) infusion every 3 weeks to 42 patients registered at four centers. Patients must have received at least one but no more than two prior chemotherapy regimens for MBC (in addition to any prior adjuvant therapy). One of the regimens for metastatic breast cancer must have included an anthracycline or anthracenedione and the cancer must have progressed on that regimen. RESULTS Objective responses were seen in 20 of 35 assessable patients (three complete responses [CRs] and 17 partial responses [PRs]), for an objective response rate of 57% (95% confidence interval [CI], 39% to 74%) and in 21 of 42 registered patients (50% response rate [RR]; 95% CI, 34% to 66%) entered onto the trial. The median response duration was 28 weeks. The most common toxicity in this study was grade 4 neutropenia, which occurred in 95% of patients. Other clinically significant nonhematologic side effects included stomatitis, skin reactions, neurosensory changes, asthenia, and fluid retention. Patients who received dexamethasone premedication had a later onset of fluid retention than those who did not receive dexamethasone (onset at a median cumulative docetaxel dose of 503 mg/m2 and 291 mg/m2, respectively). CONCLUSION Docetaxel at this dose and schedule has a high level of antitumor activity in patients with treatment-refractory advanced breast cancer, and appears to be one of the most active agents for the treatment of this patient population." @default.
• W1846747462 created "2016-06-24" @default.
• W1846747462 creator A5002717310 @default.
• W1846747462 creator A5007714289 @default.
• W1846747462 creator A5010085668 @default.
• W1846747462 creator A5011805333 @default.
• W1846747462 creator A5024576368 @default.
• W1846747462 creator A5064101566 @default.
• W1846747462 creator A5072308451 @default.
• W1846747462 creator A5080875837 @default.
• W1846747462 creator A5081340453 @default.
• W1846747462 date "1995-12-01" @default.
• W1846747462 modified "2023-10-10" @default.
• W1846747462 title "Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer." @default.
• W1846747462 cites W1907962006 @default.
• W1846747462 cites W1919221066 @default.
• W1846747462 cites W1999917113 @default.
• W1846747462 cites W2014184691 @default.
• W1846747462 cites W2036045878 @default.
• W1846747462 cites W2039086504 @default.
• W1846747462 cites W2043478531 @default.
• W1846747462 cites W2073533584 @default.
• W1846747462 cites W2154335454 @default.
• W1846747462 cites W2240623839 @default.
• W1846747462 cites W2397642728 @default.
• W1846747462 doi "https://doi.org/10.1200/jco.1995.13.12.2879" @default.
• W1846747462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8523050" @default.
• W1846747462 hasPublicationYear "1995" @default.
• W1846747462 type Work @default.
• W1846747462 sameAs 1846747462 @default.
• W1846747462 citedByCount "305" @default.
• W1846747462 countsByYear W18467474622012 @default.
• W1846747462 countsByYear W18467474622013 @default.
• W1846747462 countsByYear W18467474622014 @default.
• W1846747462 countsByYear W18467474622015 @default.
• W1846747462 countsByYear W18467474622016 @default.
• W1846747462 countsByYear W18467474622017 @default.
• W1846747462 countsByYear W18467474622018 @default.
• W1846747462 countsByYear W18467474622019 @default.
• W1846747462 countsByYear W18467474622020 @default.
• W1846747462 countsByYear W18467474622023 @default.
• W1846747462 crossrefType "journal-article" @default.
• W1846747462 hasAuthorship W1846747462A5002717310 @default.
• W1846747462 hasAuthorship W1846747462A5007714289 @default.
• W1846747462 hasAuthorship W1846747462A5010085668 @default.
• W1846747462 hasAuthorship W1846747462A5011805333 @default.
• W1846747462 hasAuthorship W1846747462A5024576368 @default.
• W1846747462 hasAuthorship W1846747462A5064101566 @default.
• W1846747462 hasAuthorship W1846747462A5072308451 @default.
• W1846747462 hasAuthorship W1846747462A5080875837 @default.
• W1846747462 hasAuthorship W1846747462A5081340453 @default.
• W1846747462 hasConcept C121608353 @default.
• W1846747462 hasConcept C126322002 @default.
• W1846747462 hasConcept C141071460 @default.
• W1846747462 hasConcept C143998085 @default.
• W1846747462 hasConcept C2775930923 @default.
• W1846747462 hasConcept C2776694085 @default.
• W1846747462 hasConcept C2776802502 @default.
• W1846747462 hasConcept C2777063308 @default.
• W1846747462 hasConcept C2778850193 @default.
• W1846747462 hasConcept C2780923524 @default.
• W1846747462 hasConcept C2781190966 @default.
• W1846747462 hasConcept C2781413609 @default.
• W1846747462 hasConcept C530470458 @default.
• W1846747462 hasConcept C71924100 @default.
• W1846747462 hasConcept C90924648 @default.
• W1846747462 hasConceptScore W1846747462C121608353 @default.
• W1846747462 hasConceptScore W1846747462C126322002 @default.
• W1846747462 hasConceptScore W1846747462C141071460 @default.
• W1846747462 hasConceptScore W1846747462C143998085 @default.
• W1846747462 hasConceptScore W1846747462C2775930923 @default.
• W1846747462 hasConceptScore W1846747462C2776694085 @default.
• W1846747462 hasConceptScore W1846747462C2776802502 @default.
• W1846747462 hasConceptScore W1846747462C2777063308 @default.
• W1846747462 hasConceptScore W1846747462C2778850193 @default.
• W1846747462 hasConceptScore W1846747462C2780923524 @default.
• W1846747462 hasConceptScore W1846747462C2781190966 @default.
• W1846747462 hasConceptScore W1846747462C2781413609 @default.
• W1846747462 hasConceptScore W1846747462C530470458 @default.
• W1846747462 hasConceptScore W1846747462C71924100 @default.
• W1846747462 hasConceptScore W1846747462C90924648 @default.
• W1846747462 hasIssue "12" @default.
• W1846747462 hasLocation W18467474621 @default.
• W1846747462 hasLocation W18467474622 @default.
• W1846747462 hasOpenAccess W1846747462 @default.
• W1846747462 hasPrimaryLocation W18467474621 @default.
• W1846747462 hasRelatedWork W1544742800 @default.
• W1846747462 hasRelatedWork W1917321041 @default.
• W1846747462 hasRelatedWork W2004163315 @default.
• W1846747462 hasRelatedWork W2087598961 @default.
• W1846747462 hasRelatedWork W2100471642 @default.
• W1846747462 hasRelatedWork W2110838388 @default.
• W1846747462 hasRelatedWork W2321926200 @default.
• W1846747462 hasRelatedWork W2398675242 @default.
• W1846747462 hasRelatedWork W2590976373 @default.
• W1846747462 hasRelatedWork W2156721214 @default.
• W1846747462 hasVolume "13" @default.
• W1846747462 isParatext "false" @default.

• next